NeuroMab™ Anti-Amyloid Beta 1-42 BBB Shuttle Antibody(NRZP-1022-ZP3653)

Figure 1 graphically depicts the results of an experiment examining the effectiveness of various antibodies, including 12A11, in clearing Aβ plaques in an in vitro phagocytosis assay.

Figure 2A graphically depicts the results of an experiment examining the effectiveness of various antibodies, including 12A11, in reducing total Aβ levels. Bars represent median values and horizontal dashed lines represent control levels.

Figure 2B graphically depicts the results of an experiment analyzing the effectiveness of various antibodies, including 12A11, in reducing neuroinflammatory dystrophy. Bars represent median values and horizontal dashed lines represent control levels. Data for individual animals are shown and expressed as percentage of neuritic dystrophy relative to the control mean (set as 100%).

Figure 3 depicts the immunoprecipitation of peroxynitrite-treated oligomeric Aβ1-42 preparations precipitated with various Aβ antibodies (3D6, 6C6, 12A11, 12B4, 3A3, 266, 9G8, 15C11, and 6H9) and imaged with 3D6 Western blot of the object. Approximate positions of Aβ1-42 monomer, dimer, trimer, and tetramer bands are shown on the left side of the Figure. Indicated below each Aβ antibody are the Aβ epitopes recognized by the antibody and the results of contextual fear conditioning (CFC) assays for the antibody, with a "+" sign indicating an increase in cognition observed after treatment with the antibody and a "-" sign indicating an increase observed with No change in cognition after antibody treatment, "+/-" sign indicates that a trend towards increased cognition was observed after antibody treatment, but the observed trend was not statistically significant enough to indicate an observed increase in cognition cognition , the "ND" symbol indicates that there is no CFC assay data for comparison for this antibody.

Figure 4 depicts proteins from immunoprecipitates of peroxynitrite-treated oligomeric Aβ1-42 preparations precipitated with various Aβ antibodies (3D6, 6C6, 12A11, 12B4, 10D5, 3A3, 266, and 6H9) and imaged with 3D6. blot. Notes are the same as in Figure 3.

Figure 5A depicts the results of the CFC assay, in which a rapid improvement in cognition was observed after administration of a single dose of murine 12A11 (1, 10 and 30 mg/kg) to Tg2576 mice.

Figure 5B depicts the results of the CFC assay in which rapid improvement in cognition was observed after administration of a single low dose of murine 12A11 (0.3 and 1 mg/kg) to Tg2576 mice.

Figure 6 depicts the results of a study in which a single dose of 12A11 (1 mg/kg) in mice was assessed for cognitive Improved duration of time (CFC) assay.

Figure 7 graphically depicts the results of an ELISA measuring the binding of chimeric 12A11, chimeric and humanized 3D6 (h3D6), and chimeric and humanized 12B4 to Aβ 1-42.

Figure 8 depicts aggregated Aβ(1-42) ELISA results comparing chimeric 12A11, humanized 12A11 v1, humanized 12A11 v2, humanized 12A11 v2.1 and humanized 12A11 v3.

Figure 9 depicts the results of a competitive Aβ1-42 ELISA binding assay comparing murine 12A11, chimeric 12A11 and h12A11 v1.

Figure 10 depicts the results of a competitive Aβ1-42 ELISA binding assay comparing murine 12A11, chimeric 12A11, h12A11 v1, h12A11 v2, h12A11 v3 and h12A11 v3.1.

Figure 11 depicts the results of the CFC assay, where a rapid improvement in cognition was observed after administration of a single dose of the humanized 12A11 antibody v3.1 h12A11 (1, 10 and 30 mg/kg) to Tg2576 mice.